Trial Profile

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of IPI-493 Orally Administered to Patients With Advanced Malignancies.

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 23 Apr 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IPI 493 (Primary)
Indications HER2 positive breast cancer; Solid tumours
Focus Adverse reactions
Sponsors Infinity Pharmaceuticals

Most Recent Events

10 Jun 2011 Planned end date changed from 1 Mar 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
10 Jun 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
30 Jun 2010 Planned end date changed from 1 May 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com